Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation procedures

Uroplasty, Inc. a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

4 Dec 2013

Researchers review effectiveness of Botox injections for overactive bladder symptoms

AN INNOVATIVE treatment helping patients with overactive bladder symptoms lead normal lives again has been licensed for use by the UK’s medicines watchdog following a landmark study in which Sheffield Teaching Hospitals NHS Foundation Trust played a leading role.

6 Nov 2013

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

18 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Overactive bladder treatments: an interview with Professor Chris Chapple, Consultant Urological Surgeon at the Royal Hallamshire Hospital and Sheffield Teaching Hospitals NHS Foundation Trust

Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.

1 Oct 2013

QoL questionnaire predicts nocturia, risk for falling

A study of Japanese outpatients highlights the association between nighttime voiding and bone fractures, after showing that the Nocturia Quality-of-Life questionnaire can identify patients at risk for both.

23 Sep 2013

Surgery shows first-line potential for stress urinary incontinence

The authors of a head-to-head study say that surgery should be considered as a first-line option for women with stress urinary incontinence, ahead of physiotherapy.

23 Sep 2013

Overactive bladder leads to underactive patients

Researchers in the USA have shown that patients with overactive bladder experience significant impairment to their physical activity levels.

2 Sep 2013

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

Tibial nerve stimulation reduces symptoms of overactive bladder, research finds

Beaumont Health System research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results published in the June issue of The Journal of Urology show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms.

31 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Perrigo receives final approval for generic Sanctura XR

Perrigo Company today announced that it has received final approval for the generic version of Sanctura XR. Perrigo had previously prevailed in litigation at both the district and appellate levels. The product has begun shipping immediately.

29 May 2013

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Frutarom Health, Switzerland, reports increased demand for Go-Less, its natural ingredient targeting urinary incontinence in adults.

28 May 2013

Uroplasty highlights results of STEP Study on PTNS treatments for overactive bladder

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation treatments for overactive bladder using Uroplasty's Urgent PC Neuromodulation System.

10 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.

5 Apr 2013

Researchers study specific bacteria that contribute to overactive bladder

Thousands of women suffer from overactive bladder (OAB) or the sudden need to urinate, yet many don't get relief from medication. Researchers at Loyola University Health System believe certain bacteria may be to blame.

4 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Previously unknown cell discovered in the urethra of mice

A recent study conducted by a group of German scientists revealed the presence of a previously unknown cell in the urethra of mice. These chemosensory cholinergic brush cells are in close contact to sensory neurons that express cholinergic receptors.

15 Mar 2013